黑色素瘤新辅助全身治疗:国际新辅助黑色素瘤联盟推荐
国际新辅助黑色素瘤联盟由肿瘤内科、外科肿瘤、病理、放射肿瘤、影像和转化研究专家组成,针对临床可检测的III期黑色素瘤新辅助治疗试验设计、终点和相关性分析提出推荐,以统一未来试验设计与分析,优化数据组织并加强转化研究。
要点
- 临床可检测的III期黑色素瘤患者是高危人群,单纯 upfront 手术结局差,为新辅助治疗的理想候选。
- 新辅助治疗在黑色素瘤是活跃研究领域,自2014年以来多项已完成和进行中的试验设计、终点和分析各异。
- 联盟推荐旨在统一未来新辅助试验设计和相关性分析,以利于监管审评和转化研究。
核心结论
- 国际新辅助黑色素瘤联盟发布推荐,以统一黑色素瘤新辅助治疗试验的设计和相关性分析,优化未来监管审评所需的数据组织,并加强黑色素瘤疾病连续体的转化研究。
研究设计与样本
- 国际新辅助黑色素瘤联盟由肿瘤内科、外科肿瘤、病理、放射肿瘤、影像和转化研究专家组成,制定关于黑色素瘤新辅助治疗研究设计的推荐。
临床应用与阅片要点
- 对于临床可检测的III期黑色素瘤患者,可考虑新辅助治疗作为改善手术可操作性和临床结局的研究策略。
- 未来新辅助试验应采用联盟推荐以统一设计、终点和相关性分析,便于数据组织和监管审评。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of response and toxicity. Neoadjuvant therapy for regional metastases might improve operability and clinical outcomes over upfront surgery and adjuvant therapy, and has become an established role for drug development and biomarker discovery in other cancers (including locally advanced breast cancer, head and neck squamous cell carcinomas, gastroesophageal cancer, and anal cancer). Patients with clinically detectable stage III melanoma are ideal candidates for neoadjuvant therapy, because they represent a high-risk patient population with poor outcomes when treated with upfront surgery alone. Neoadjuvant therapy is now an active area of research for melanoma with numerous completed and ongoing trials (since 2014) with disparate designs, endpoints, and analyses under investigation. We have, therefore, established the International Neoadjuvant Melanoma Consortium with experts in medical oncology, surgical oncology, pathology, radiation oncology, radiology, and translational research to develop recommendations for investigating neoadjuvant therapy in melanoma to align future trial designs and correlative analyses. Alignment and consistency of neoadjuvant trials will facilitate optimal data organisation for future regulatory review and strengthen translational research across the melanoma disease continuum.
引用
- Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019. PMID: 31267972. doi:10.1016/S1470-2045(19)30332-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。